In-Silico Protein-Ligand Docking Studies against the NS5 Methyltransferase Protein of Dengue Virus

  IJCTT-book-cover
 
International Journal of Computer Trends and Technology (IJCTT)          
 
© 2018 by IJCTT Journal
Volume-62 Number-1
Year of Publication : 2018
Authors : Nidhi Katiyar, Ravindra Nath
  10.14445/22312803/IJCTT-V62P103

MLA

MLA Style: Nidhi Katiyar, Ravindra Nath "In-Silico Protein-Ligand Docking Studies against the NS5 Methyltransferase Protein of Dengue Virus" International Journal of Engineering Trends and Technology 62.1 (2018): 21-29.

APA Style: Nidhi Katiyar, Ravindra Nath (2018). In-Silico Protein-Ligand Docking Studies against the NS5 Methyltransferase Protein of Dengue Virus. International Journal of Engineering Trends and Technology, 62(1), 21-29.

Abstract
From last few decade dengue viruses is the most significant arthropod-borne human pathogen. We found that the number of cases have been increased and reported in every year. Currently vaccines and drugs against the dengue viruses are available in rare quantity and till now people are depend on the natural drugs that may or may not be beneficiary for the patient. In this study, the problem of designing the drug molecule against the dengue virus has been solved in-silico protein-ligand docking using computational method. We found some potential lead compounds which are active against dengue virus. After the molecular docking we perform the virtual screening and get thousand analogs of lead compounds. The interactions of the analogs with the active site of 1L9K and 1R6A protein were analyzed. On the basis of activity and high binding interactions to find some best compounds which suggested new drug candidate for the future plan.

Reference
[1] Gubler DJ: Dengue and dengue hemorrhagic fever.Clin Microbial Rev 1998, 11(3):480-496.
[2] Ligon BL: Dengue fever and dengue hemorrhagic fever: a review of the history, transmission, treatment, and prevention.SeminPediatr Infect Dis 2005, 16(1):60-65.
[3] Luzhkov VB, Selisko B, Nordqvist A, Peyrane F, Decroly E, Alvarez K, Karlen A, Canard B, Qvist J: Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2’O)-methyltransferase.Bioorg Med Chem 2007, 15(24):7795-7802.
[4] Geiss BJ, Thompson AA, Andrews AJ, Sons RL, Gari HH, Keenan SM, and Peersen OB: Analysis of flavivirus NS5 methyltransferase cap binding. J MolBiol 2009, 385(5):1643-1654.
[5] S.RobertsDipanker Bhattacharya: DENGUE NS5- Methyltransferase target. J Med Chem 2010.
[6] Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, Guo Y, Bernard KA, Shi PY, Li H: Structure and function of flavivirus NS5 methyltransferase. J Virol 2007, 81(8):3891-3903.
[7] Kasam V, Zimmermann M, Maass A, Schwichtenberg H, Wolf A, Jacq N, Breton V,Hofmann-Apitius M: Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid. J ChemInf Model 2007, 47(5):1818-1828.
[8] Podvinec M, Lim SP, Schmidt T, Scarsi M, Wen D, Sonntag LS, Sanschagrin P, Shenkin PS, Schwede T: Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid. J Med Chem 2010, 53(4):1483-1495.
[9] Differential binding of S-adenosylmethionine S adenosylhomocysteine and Sinefungin to the adenine-specific DNA methyltransferaseM.TaqI: G. Schluckebier, et al. J. Mol. Biol. 265, 56 (1997).
[10] Podvinec, M.; Schwede, T.; Peitsch, M. C. Docking for neglected diseases as community efforts. In Computational Structural Biology: Methods and Applications;Schwede, T.; Peitsch, M. C., Eds.; World Scientific Publishing: Singapore, 2008; pp 683− 704.
[11] Fornsworth: Aurintricarboxylicacid inhibit the serve acute respiratory syndrome associated Coronavirus (SARS-CoV) and vaccinia virus Inhibitors Res. 2007.
[12] M.Taqi G. Schluckebier, 1997: Sinefungin, a known inhibitor of protein methylation.
[13] Noureen N; Rashid H; Kalsoom S. Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemotherapy and Pharmacology 2010, 66, 625–633.
[14] Pang T: Vaccines for the prevention of neglected diseases–dengue fever. CurrOpinBiotechnol 2003, 14(3):332-336.
[15] Halstead SB, Deen J: The future of dengue vaccines. Lancet 2002, 360(9341):1243-1245.
[16] Dong, H.; Zhang, B.; Shi, P. Y. Flavivirusmethyltransferase: A novel antiviral target Antiviral Res. 2008, 80 (1) 1– 10 [CrossRef], [PubMed], [CAS].
[17] SV Lim, MohdBasyaruddin AR, Bimo AT: Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus. BMC Bioinformatics 2011,12(Suppl 13):S24
[18] Podvinec M, Lim SP, Schmidt T, Scarsi M, Wen D, Sonntag LS, Sanschagrin P, Shenkin PS, Schwede T: Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid. J Med Chem 2010, 53(4):1483-1495.
[19] Lim SP, Sonntag LS, Noble C, Nilar SH, Ng RH, Zou G, Monaghan P, Chung KY, Dong H, Liu B, et al: Small molecule inhibitors that selectively block dengue virus methyltransferase. J BiolChem 2011, 286(8):6233-6240.
[20] Subramaniam S, Mehrotra M, Gupta D: Virtual high throughput screening (vHTS)–a perspective. Bioinformation 2008, 3(1):14-17.
[21] Chang MW, Lindstrom W, Olson AJ, Belew RK: Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries. J ChemInf Model 2007, 47(3):1258-1262.
[22] NidhiKatiyar, RavindraNath, Methods for Protein Structure Prediction and Its Application in Drug Design Using Hidden Markov Model,International Journal of Emerging Trends in Science and Technology. IJETST 2016; ISSN2348-9480.
[23] rott O, Olson AJ: AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J ComputChem 2010, 31(2):455-461.
[24] Han LY, Lin HH, Li ZR, Zheng CJ, Cao ZW, Xie B, Chen YZ: PEARLS: program for energetic analysis of receptor-ligand system. J ChemInf Model 2006, 46(1):445-450.
[25] Wallace AC, Laskowski RA, and Thornton JM: LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995, 8(2):127-134. 44.
[26] Shave SR: The development of high performances structure and ligand based virtual screening techniques. PhD Thesis Edinburgh: University of Edinburgh; 2009.
[27] Cleaves GR, Dubin DT: Methylation status of intracellular dengue type 2 40 S RNA. Virology 1979, 96(1):159-165.
[28] Ray D, Shah A, Tilgner M, Guo Y, Zhao Y, Dong H, Deas TS, Zhou Y, Li H, Shi PY: West Nile virus 5’-cap structure is formed by sequential guanine N-7 and ribose 2’-O methylations by nonstructural protein 5. J Virol 2006, 80(17):8362-8370.
[29] Guo JT, Hayashi J, Seeger C: West Nile virus inhibits the signal transduction pathway of alpha interferon. J Virol 2005, 79(3):1343-1350.
[30] Padmanabhan R, Mueller N, Reichert E, Yon C, Teramoto T, Kono Y, Takhampunya R, Ubol S, Pattabiraman N, Falgout B, et al: Multiple enzyme activities of flavivirus proteins. Novartis Found Symp 2006, 277:74-84, discussion 84-76, 251-

Keywords
Methyltransferase (MTase); NS5 (Nonstructural protein); DENV (Dengue virus); RTP (Ribavirin triphosphate); SAH (S-Adenosyl-L-homocysteine); PDB (Protein Data Bank).